Nazila Bahmaie

Dr. Nazila Bahmaie

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AEAbdolreza Esmaeilzadeh
Abdolreza Esmaeilzadeh
NBNazila Bahmaie
Nazila Bahmaie
ENElham Nori
Elham Nori
MHMohammad Javad Hajkazemi
Mohammad Javad Hajkazemi
MRMaryam Zareh Rafie
Maryam Zareh Rafie
Exponential growth in the usage of “cytokines” (as seroimmunobiomarkers) has facilitated more accurate prognosis, early diagnosis, novel, and efficient immunotherapeutics. Numerous studies have reported immunopathophysiological and immunopathological processes of interleukin-38 (IL-38). Therefore, in this systematic review article, the authors aimed to present an updated comprehensive overview on the immunobiological mechanisms, diagnostic, and immune gene-based therapeutic potentials of IL-38. According to our inclusion and exclusion criteria, a total of 216 articles were collected from several search engines and databases from the January 2012 to July 2021 time interval by using six main keywords. Physiologic or pathologic microenvironments, optimal dosage, and involved receptors affect the functionalities of IL-38. Alterations in serum levels of IL-38 play a major role in the immunopathogenesis of a wide array of immune-mediated disorders. IL-38 shows anti-inflammatory activities by reduction or inhibition of pro-inflammatory cytokines, supporting the therapeutic aspects of IL-38 in inflammatory autoimmune diseases. According to the importance of pre-clinical studies, it seems that manipulation of the immune system by immunomodulatory properties of IL-38 can increase the accuracy of diagnosis, and decipher optimal clinical outcomes. To promote our knowledge, more collaboration is highly recommended among laboratory scientists, internal/infectious diseases specialists, oncologists, immunologists, diseases-specific biomarkers scientists, and basic medical researchers.

1 June 2021 in International Immunopharmacology
Verified
Journal Article
Closed access
ZZZeineb Zian
Zeineb Zian
SBS.P. Déo-Gracias Berry
S.P. Déo-Gracias Berry
NBNazila Bahmaie
Nazila Bahmaie
DGDana Ghotbi
Dana Ghotbi
AKAli Kashif
Ali Kashif
GAGholamreza Azizi
Gholamreza Azizi

11 October 2024 in The Journal of Liquid Biopsy
Verified
Journal Article
Open access
NBNazila Bahmaie
Nazila Bahmaie
OGOzen Ozensoy Guler
Ozen Ozensoy Guler
EŞEnder Şimşek
Ender Şimşek
Despite a substantial progress in the development of strategies against cancer, cancer still remains a major global health issue due to a high recurrence rate, and severe side effects, leading basic medical scientists and clinical specialists toward more efficient diagnostics, prognostics, and therapeutics. Therefore, there is an imperative need for a comprehensive understanding on the cellular immunopathophysiology involved in the tumor microenvironment. In addition, results from a wide range of studies depicted that an aberration in the cellular mechanisms and immunopathophysiological interactions like Circulating Tumor Cells (CTCs) plays an indispensable role in the metastasis and tumor progression, revolutionizing cancer management by offering non-invasive detection methods and a real-time monitoring of tumor dynamics. Moreover, CTCs can clarify the tumor heterogeneity and the evolution of resistance mechanisms, aiding in the early detection of tumors and informing personalized treatment strategies. An increase in CTCs count can be associated with a worsened cancer prognosis, providing promising biomarkers for tumor phenotyping, tumor spreading or relapse, and monitoring the treatment response in patients with cancer. Hence, this systematic review aims to highlight the diagnostic, prognostic, and therapeutic potentials of CTCs, necessitating further investigations and an interdisciplinary collaboration among basic medical scientists and oncologists to address the current gaps in the strategies of cancer management, precisely improving patient-care and optimized clinical outcomes.

13 April 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
FRFarid Rajaee Rizi
Farid Rajaee Rizi
MJMaryam Sadat Jamadi
Maryam Sadat Jamadi
SRSamin Rahimi
Samin Rahimi
MBMoein Bighamian
Moein Bighamian
POUYA PAIDARPOUYA PAIDAR
POUYA PAIDAR
NBNazila Bahmaie
Nazila Bahmaie
Precision oncology in urology increasingly depends on integrating heterogeneous data, including multiparametric imaging, histopathology, genomics, and clinical variables. Multimodal artificial intelligence (AI) offers a unified framework to manage this complexity, supporting refined risk stratification, personalized treatment decisions, and informed patient counseling. This narrative review examines applications of multimodal AI in prostate, bladder, and kidney cancers. Beyond listing individual tools, we emphasize how synergistic data fusion enhances the validation of diagnostic and prognostic performance. Clinical advances include more accurate tumor delineation on multiparametric MRI and predictive modeling of functional outcomes after surgery, underscoring the translational potential of these systems. However, major barriers hinder clinical adoption. Prospective validation remains scarce, data harmonization across institutions are limited, and the opaque nature of many algorithms fuels skepticism among clinicians. These factors collectively restrict the integration of multimodal AI into routine clinical practice. Closing this gap requires standardized data curation, development of interpretable and transparent models, and the design of collaborative human–AI workflows. Ultimately, successful translation will depend not only on technical progress but also on redefining trust and expertise in urologic oncology, ensuring that algorithmic insights are meaningfully aligned with bedside decision-making.

29 June 2020 in Iranian Journal of Allergy, Asthma and Immunology
Verified
Journal Article
Open access
PDF file
EKElnaz Khosh
Elnaz Khosh
NBNazila Bahmaie
Nazila Bahmaie
REReza Elahi
Reza Elahi
AEAbdolreza Esmaeilzadeh
Abdolreza Esmaeilzadeh
Recently, the era of medicine has been encountered with the exponential growth of special seroimmunobiomarkers in clinical trials. Lately, Interleukin-37 (IL-37) has attracted a wide range of basic medical scientists’ attention due to its controversial functions in physiologic or pathologic microenvironments. In this research, an updated overview of immunobiological functions and clinical applications of IL-37 in a wide range of diseases, are discussed in order to highlight the role of recent laboratory-based results of IL-37. Data of this systematic review article were collected from initial 237 articles in Google Scholar search engine, Science Direct, PubMed, Scopus, and Embase databases. Eventually, 134 total articles were considered from March 2000 to June 2019 time interval, by using 5 keywords. Relevant English articles, abstracts and conference papers all were included. No restrictions of methods and type of the article were imposed. As one of the newly immunotherapeutic based approaches, clinical applications of cytokines are promisingly taken into account for diagnosis and treatment of multiple diseases. Various evidence suggests that IL-37 has notable roles in the regulation of acute and chronic inflammatory responses. Also, IL-37 has been studied in pregnancy, obesity, infectious, cardiovascular, neurologic, autoimmune, and metabolic diseases. Also, the protective functions of IL-37 against multiple cancers, are disputably related to the type and stage of cancer as well as the IL-37 variant. The broad spectrum of IL-37 and its receptors in diseases, seem to be a potential candidate with pivotal effects for immunomodulation and immune gene therapy of various pathologic states.

1 January 2022 in The Eurasian Journal of Medicine
Verified
Journal Article
Open access
NDNahid Daneshi
Nahid Daneshi
AEAbdolreza Esmaeilzadeh
Abdolreza Esmaeilzadeh
NBNazila Bahmaie
Nazila Bahmaie
Along with the high transmission rate of coronavirus disease 2019 infection in the last few months, the morbidity and mortality rate of coronavirus disease 2019 has been increased among critically-ill patients, especially the elderly or the ones with immunodeficiencies. So, there is an urgent need to develop more effective therapeutic agents through immunopathophysiological and immunotherapeutic-based strategies for these patients. Here, we hypothesize that mixing S1b-RBD-expressing mesenchymal stem cell-derived exosomes (which have been previously enriched with Remdesivir) with 47D11 antibody, can promisingly guarantee effective transferring of those targeted exosomes to the targeted microenvironment of coronavirus disease 2019 infection. In addition, it can induce their immunomodulatory properties, and anti-viral features, refraining from entrance of severe acute respiratory syndrome-related coronavirus-2 to angiotensin-converting enzyme 2-expressing cells. Cite this article as: Daneshi N, Esmaeilzadeh A, Bahmaie, N. 47D11 antibody-engineered exosomes for targeted delivery of remdesivir in patients with COVID-19: Dream or principle? (A critical editorial study). Eurasian J Med., 2022;54(3):310-312.